{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:21:15Z","timestamp":1789849275591,"version":"4.0.1"},"reference-count":4,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK072482"],"award-info":[{"award-number":["DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The CFTR potentiator ivacaftor is responsible for significant clinical improvements among a subset of patients with cystic fibrosis. Because it is a substrate of the cytochrome P450 system, specifically CYP3A4\/5, ivacaftor is subject to significant drug\u2010drug interactions, including due to commonly used antimicrobials such as rifampin. While the interaction of rifampin and ivacaftor has been examined in vitro, severe adverse events resulting from this interaction have not been reported in the literature. In this report, we describe the termination of steady, long\u2010term improvement in a patient taking ivacaftor, resulting from the use of rifampin and precipitating a significant pulmonary exacerbation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.23971","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T11:48:48Z","timestamp":1519818528000},"source":"Crossref","is-referenced-by-count":25,"title":["Sensitivity of ivacaftor to drug\u2010drug interactions with rifampin, a cytochrome P450 3A4 inducer"],"prefix":"10.1002","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-8536","authenticated-orcid":false,"given":"Jennifer S.","family":"Guimbellot","sequence":"first","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham (UAB) Birmingham Alabama"},{"name":"Department of Pediatrics Division of Pulmonary and Sleep Medicine University of Alabama at Birmingham (UAB) Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham (UAB) Birmingham Alabama"},{"name":"Department of Pharmacology and Toxicology University of Alabama at Birmingham (UAB) Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-0133","authenticated-orcid":false,"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham (UAB) Birmingham Alabama"},{"name":"Department of Pediatrics Division of Pulmonary and Sleep Medicine University of Alabama at Birmingham (UAB) Birmingham Alabama"},{"name":"Departments of Medicine and Cell Developmental and Integrative Biology University of Alabama at Birmingham (UAB) Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30047-9"},{"key":"e_1_2_8_3_1","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","author":"Trimble AT","year":"2017","journal-title":"J Cyst Fibros"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23505"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.377"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fppul.23971","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.23971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T11:59:06Z","timestamp":1694951946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.23971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/ppul.23971"],"URL":"https:\/\/doi.org\/10.1002\/ppul.23971","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]}}}